Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Hervé_Hoppenot
|
| gptkbp:collaboratedWith |
gptkb:Eli_Lilly_and_Company
gptkb:Merck_&_Co. gptkb:Novartis |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:founded |
1991
|
| gptkbp:founder |
gptkb:Roy_Whitfield
|
| gptkbp:headquartersLocation |
gptkb:Wilmington,_Delaware,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Incyte
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:marketCap |
over $15 billion (2024)
|
| gptkbp:notableProduct |
gptkb:Jakafi
gptkb:Opzelura gptkb:Pemazyre |
| gptkbp:numberOfEmployees |
over 2,000
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
oncology
inflammation autoimmunity |
| gptkbp:revenue |
$3.7 billion (2023)
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:INCY
|
| gptkbp:subsidiary |
gptkb:Incyte_Biosciences_International_Sàrl
|
| gptkbp:website |
https://www.incyte.com/
|
| gptkbp:bfsParent |
gptkb:礼来公司
gptkb:MorphoSys |
| gptkbp:bfsLayer |
5
|